Skip to content
value.today

BioSig Technologies, Inc.

🇺🇸 Los Angeles, California, USABiotechnologyFounded 2011
Total raised
$8 M
3 rounds on record
Latest round
$1 M
Oct 2015
First round on record
Feb 2013
Today
Went public
See the company page

BioSig Technologies, Inc. is listed today as Streamex Corp.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 20 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BioSig Technologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$3 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, May 2024

Investors in this round

4 investors had bought by the notice of Jun 6, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$240,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony Amato · Executive Officer, Director · Chief Executive Officer
  • Frederick D. Hrkac · Executive Officer, Director · Acting Chief Financial Officer
  • Chris F. Baer · Director
  • Donald F. Browne · Director
  • Steven E. Abelman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 000000375) · New York, New YorkSold in CA, IL, and outside the US

Remarks in the notice

  • On fees: “"H.C. Wainwright & Co. (""HCW"") acted as exclusive placement agent for the offering. HCW received a cash fee equal to 7.0% of the gross proceeds of the offering and a management fee equal to 1.0% of the gross proceeds raised in the offering."”
  • On the amounts: “Represents total gross proceeds received by the company in connection with a registered direct offering of shares of common stock and a concurrent private placement of common stock purchase warrants.”

Signed by Anthony Amato, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2024. Read the notice at the SEC.

optionsSEC
May 2024$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, May 2024

Investors in this round

6 investors had bought by the notice of Jun 6, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony Amato · Executive Officer, Director · Chief Executive Officer
  • Frederick D. Hrkac · Executive Officer · Acting Chief Financial Officer
  • Chris F. Baer · Director
  • Donald F. Browne · Director
  • Steven E. Abelman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold 783,406 shares of common stock at a purchase price of $1.4605 per share and warrants to purchase up to 391,703 shares at an exercise price of $1.398 per share. $509,165 of the purchase price was paid by the conversion of an outstanding note.”

Signed by Anthony Amato, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2024. Read the notice at the SEC.

equity, optionsSEC
Jan 2024$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Jan 2024

Investors in this round

7 investors had bought by the notice of Jan 16, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold 2,607,170 shares at a purchase price of $0.3989 per share and warrants to purchase up to 1,303,585 shares at an exercise price of $0.3364 per share. Amount includes $438,525.99 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 16, 2024. Read the notice at the SEC.

equity, optionsSEC
Sep 2023$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Sep 2023

Investors in this round

10 investors had bought by the notice of Oct 6, 2023: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$30,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 40,511 shares of common stock.”
  • On the amounts: “Issuer sold 1,458,770 shares at a purchase price of $0.5554 per share and warrants to purchase up to 729,385 shares at an exercise price of $0.4929 per share. Amount includes $359,513.87 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2023$2 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Jul 2023

Investors in this round

1 investor had bought by the notice of Aug 1, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 110,072 shares of common stock.”
  • On the amounts: “Issuer sold 1,467,624 shares at a purchase price of $1.02206 per share and warrants to purchase up to 733,812 shares at an exercise price of $0.95956 per share. Amount includes $704,136.64 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 1, 2023. Read the notice at the SEC.

equity, optionsSEC
May 2023$4 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, May 2023

Investors in this round

20 investors had bought by the notice of May 26, 2023: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$104,617
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in FL, IL, OH, PA

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 62,698 shares of common stock.”
  • On the amounts: “Issuer sold 1,798,452 shares at a purchase price of $1.3905 per share and warrants to purchase up to 899,226 shares at an exercise price of $1.328 per share. Amount includes $1,194,172.13 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed May 26, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2023$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Apr 2023

Investors in this round

14 investors had bought by the notice of Apr 28, 2023: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$11,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in no state named, and outside the US

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 7,862 shares of common stock.”
  • On the amounts: “Issuer sold 792,454 shares at a purchase price of $1.1925 per share and warrants to purchase up to 396,227 shares at an exercise price of $1.13 per share. Amount includes $447,736.51 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2023. Read the notice at the SEC.

equity, optionsSEC
Mar 2023$2 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Mar 2023

Investors in this round

5 investors had bought by the notice of Apr 5, 2023: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$64,610
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 49,465 shares of common stock.”
  • On the amounts: “Issuer sold 935,130 shares at a purchase price of $1.0885 per share and warrants to purchase up to 467,565 shares at an exercise price of $1.026 per share. Amount includes $479,721.69 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2023. Read the notice at the SEC.

equity, optionsSEC
Mar 2023$3 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Mar 2023

Investors in this round

17 investors had bought by the notice of Mar 20, 2023: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 67,611 shares of common stock.”
  • On the amounts: “Issuer sold 1,550,540 shares at a purchase price of $1.10928 per share and warrants to purchase up to 775,270 shares at an exercise price of $1.04678 per share. Amount includes $811,537 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 20, 2023. Read the notice at the SEC.

equity, optionsSEC
Feb 2023$2 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Feb 2023

Investors in this round

7 investors had bought by the notice of Feb 13, 2023: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$80,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J Buhaly · Executive Officer · Chief Financial Officer
  • David J Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in NV

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 87,331 shares of common stock.”
  • On the amounts: “Issuer sold 1,591,750 shares at a purchase price of $0.8588 per share and warrants to purchase up to 795,875 shares at an exercise price of $0.7963 per share. Amount includes $633,755 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 13, 2023. Read the notice at the SEC.

equity, optionsSEC
Jan 2023$2 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Jan 2023

Investors in this round

1 investor had bought by the notice of Jan 31, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$104,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steve L. Chaussy · Executive Officer · Chief Financial Officer
  • David L. Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 124,904 shares of common stock.”
  • On the amounts: “Issuer sold 1,665,384 shares at a purchase price of $0.7806 per share and warrants to purchase up to 832,692 shares at an exercise price of $0.7181 per share. Amount includes $597,956 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 31, 2023. Read the notice at the SEC.

equity, optionsSEC
Jan 2023$2 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Jan 2023

Investors in this round

17 investors had bought by the notice of Feb 13, 2023: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$43,760
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steven J. Buhaly · Executive Officer · Chief Financial Officer
  • David L. Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CA, OH, PA, TX

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 71,214 shares of common stock.”
  • On the amounts: “Issuer sold an aggregate of 2,178,316 shares at a purchase price of $0.57608 per share and warrants to purchase up to 1,809,158 shares at an exercise price of $0.51358 per share. Amount includes $559,370 that may be received upon exercise of the warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 13, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2022$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Dec 2022

Investors in this round

8 investors had bought by the notice of Jan 4, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$40,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steve L. Chaussy · Executive Officer · Chief Financial Officer
  • David L. Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 49,213 shares of common stock.”
  • On the amounts: “Issuer sold 2,161,598 shares of common stock and warrants to purchase up to 1,080,799 shares of common stock at a combined purchase price of $0.508 per share and accompanying warrant. The amount doesn't include proceeds from the exercise of such warrants.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2022$1 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Nov 2022

Investors in this round

10 investors had bought by the notice of Dec 30, 2022: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$40,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Sieckhaus · Executive Officer · Chief Operating Officer
  • Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer
  • Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer
  • Steve L. Chaussy · Executive Officer · Chief Financial Officer
  • David L. Weild IV · Director
  • Donald E. Foley · Director
  • Frederick D. Hrkac · Director
  • James J. Barry · Director
  • James L. Klein · Director
  • Patrick J. Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · Boca Raton, FloridaSold in OH

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 60,976 shares of common stock.”
  • On the amounts: “The issuer sold an aggregate of 3,541,469 shares of common stock at $0.41 per share to certain accredited investors.”

Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 30, 2022. Read the notice at the SEC.

equitySEC
Aug 2019$3 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Aug 2019

Investors in this round

17 investors had bought by the notice of Aug 20, 2019: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Andrew Filler · Director
  • David Weild · Director
  • Donald Foley · Director
  • Jeffrey O'Donnell · Director
  • Jerome Zeldis · Director
  • Patrick Gallagher · Director
  • Samuel Navarro · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 20, 2019. Read the notice at the SEC.

equitySEC
Mar 2019$9 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Mar 2019

Investors in this round

103 investors had bought by the notice of Mar 28, 2019: 103 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Andrew Filler · Director
  • David Weild · Director
  • Donald Foley · Director
  • Jeffrey ODonnell · Director
  • Patrick Gallagher · Director
  • Roy Tanaka · Director
  • Seth Fischer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steve Chaussy, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 28, 2019. Read the notice at the SEC.

equitySEC
Aug 2018$4 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Aug 2018

Investors in this round

72 investors had bought by the notice of Aug 28, 2018: 72 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$150,035
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Andrew Filler · Director
  • David Weild · Director
  • Donald Foley · Director
  • Jeffrey O'Donnell · Director
  • Patrick Gallagher · Director
  • Roy Tanaka · Director
  • Seth Fischer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AR, CA, CT, FL, GA, IL, MA, MD, MN, NJ, NV, NY, TX, WA

Remarks in the notice

  • On fees: “Laidlaw is also entitled to warrants to purchase up to 285,172 shares of the Company's common stock.”

Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2018. Read the notice at the SEC.

equity, optionsSEC
Feb 2018$2 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Feb 2018

Investors in this round

2 investors had bought by the notice of Feb 27, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Andrew Filler · Director
  • David Weild · Director
  • Donald Foley · Director
  • Jeffrey O'Donnell · Director
  • Patrick Gallagher · Director
  • Roy Tanaka · Director
  • Seth Fischer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 27, 2018. Read the notice at the SEC.

equity, optionsSEC
Nov 2017$2 MPrivate placement after listing$2 to $10 million

BioSig Technologies, Inc.: Private sale, Nov 2017

Investors in this round

2 investors had bought by the notice of Nov 17, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Andrew Filler · Director · Director
  • David Weild · Director · Director
  • Donald Foley · Director · Director
  • Jeffrey O'Donnell · Director · Director
  • Patrick Gallagher · Director · Director
  • Roy Tanaka · Director · Director
  • Seth Fischer · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 17, 2017. Read the notice at the SEC.

equity, optionsSEC
Apr 2017$2 MPrivate placement after listingUnder $2 million

BioSig Technologies, Inc.: Private sale, Apr 2017

Investors in this round

22 investors had bought by the notice of Jul 20, 2017: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $7 M offered; $5 M still to sell
Smallest investment taken
$15,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • David Weild · Director · Director
  • Donald Foley · Director · Director
  • Jeffrey O'Donnell · Director · Director
  • Jerome Zeldis · Director · Director
  • Patrick Gallagher · Director · Director
  • Roy Tanaka · Director · Director
  • Seth Fischer · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This represents aggregate consideration of $1,640,398 received in connection with the Issuer's closings occurring between April 6, 2017 and July 13, 2017.”

Signed by Kenneth Londoner, Executive Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 20, 2017. Read the notice at the SEC.

equity, optionsSEC
Oct 2015$1 MNo. 3Under $2 million

BioSig Technologies, Inc.: Raise no. 3, Oct 2015

Investors in this round

14 investors had bought by the notice of Nov 23, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $7 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$59,400
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory Cash · Executive Officer, Director · President and Chief Executive Officer
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • David Foley · Director
  • David Weild · Director
  • Jeffrey O'Donnell · Director
  • Jerome Zeldis · Director
  • Kenneth Londoner · Director
  • Patrick Gallagher · Director
  • Roy Tanaka · Director
  • Seth Fischer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CA, CT, LA, MA, MI, MN, NJ, NY

Remarks in the notice

  • On the amounts: “This represents consideration of $325,000, $130,000 and $565,000 for the Issuer's first, second and third closing occurring on October 23, 2015, October 29, 2015 and November 18, 2015, respectively.”

Signed by Gregory Cash, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 23, 2015. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$4 MNo. 2$2 to $10 million

BioSig Technologies, Inc.: Raise no. 2, Dec 2014

Investors in this round

107 investors had bought by the notice of Apr 3, 2015: 107 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$481,080
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory Cash · Executive Officer, Director · President and Chief Executive Officer
  • Kenneth Londoner · Executive Officer, Director
  • Steve Chaussy · Executive Officer · Chief Financial Officer
  • Asher Holzer · Director
  • Jeffrey O'Donnell · Director
  • Jonathan Steinhouse · Director
  • Patrick Gallagher · Director
  • Roy Tanaka · Director
  • Seth Fischer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AR, CA, CT, DC, FL, GA, IL, IN, KS, LA, MA, ME, MI, NC, NE, NJ, OH, OK, PA, SC, TN, TX, VA, WV, and outside the US

Remarks in the notice

  • On fees: “The Issuer also issued five-year warrants to purchase a total of 400,900 shares of common stock at an exercise price of $3.75 per share to the placement agent as consideration for serving as the placement agent.”
  • On the amounts: “This represents consideration of $339,500, $172,600,$1,071,000, $842,500, $557,500 and $1,025,900 for the Issuer's first, second, third, fourth, fifth and sixth closing, occurring on 12/19/14,12/30/14, 1/27/15, 2/10/15, 2/27/15 and 3/31/15 respectively.”

Signed by Gregory Cash, President and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Apr 3, 2015. Read the notice at the SEC.

equity, optionsSEC
Feb 2013$3 MNo. 1$2 to $10 million

BioSig Technologies, Inc.: Raise no. 1, Feb 2013

Investors in this round

41 investors had bought by the notice of Jul 26, 2013: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$166,860
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Asher S Holzer · Executive Officer, Director
  • Budimir S Drakulic · Executive Officer, Director
  • Kenneth Londoner · Executive Officer, Director
  • Lora S Mikolaitis · Executive Officer
  • Jeffrey S O'Donnell · Director
  • Jonathan S Steinhouse · Director
  • Kalyanam S Shivkumar · Director
  • Roy S Tanaka · Director
  • Seth S Fischer · Director
  • William S Uglow · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AR, CA, CO, CT, DE, FL, IA, IL, IN, KY, MA, NJ, NV, NY, OH, OK, PA, TX, WI, and outside the US

Remarks in the notice

  • On fees: “The Issuer also issued a five-year warrant to purchase 177,057 shares of common stock at an exercise price of $2.61 per share to the placement agent as consideration for serving as the placement agent.”
  • On the amounts: “$600,000 of the amount sold represented conversion of outstanding indebtedness.”

Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Jul 26, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Streamex Corp., its revenue in fiscal 2024 came from these business segments: Corporate $40,000 (100%).

    Annual report (SEC XBRL) · Dec 2024

  • BioSig Technologies, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2024

Products and services#

No products or services of BioSig Technologies, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in BioSig Technologies, Inc.
InvestorKindAmountRoundRoleSource
Jerome B. ZeldisPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 107 investors.

Largest shareholders today

Institutions holding Streamex Corp. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioSig Technologies, Inc.
NameRoleNamed in
Anthony AmatoChief Executive OfficerJun 2024
Frederick D. HrkacActing Chief Financial OfficerJun 2024
John L. SieckhausChief Operating OfficerJan 2024
Kenneth L. LondonerChairman and Chief Executive OfficerJan 2024
Michael Graydon Fleming, Jr.Chief Commercial OfficerJan 2024
Steven J BuhalyChief Financial OfficerJan 2024
Steven J. BuhalyChief Financial OfficerFeb 2023
Steve L. ChaussyChief Financial OfficerJan 2023
Kenneth LondonerChief Executive Officer and Director of the IssuerAug 2019
Steve ChaussyChief Financial OfficerAug 2019
Gregory CashPresident and Chief Executive OfficerNov 2015
Asher S HolzerExecutive officerJul 2013
Budimir S DrakulicExecutive officerJul 2013
Lora S MikolaitisExecutive officerJul 2013
Anthony AmatoChief Executive OfficerJun 2024
Chris F. BaerDirectorJun 2024
Donald F. BrowneDirectorJun 2024
Frederick D. HrkacActing Chief Financial OfficerJun 2024
Steven E. AbelmanDirectorJun 2024
David J Weild IVDirectorJan 2024
Donald E. FoleyDirectorJan 2024
James J. BarryDirectorJan 2024
James L. KleinDirectorJan 2024
Kenneth L. LondonerChairman and Chief Executive OfficerJan 2024
Patrick J. GallagherDirectorJan 2024
David L. Weild IVDirectorFeb 2023
Andrew FillerDirectorAug 2019
David WeildDirectorAug 2019
Donald FoleyDirectorAug 2019
Jeffrey O'DonnellDirectorAug 2019
Jerome ZeldisDirectorAug 2019
Kenneth LondonerChief Executive Officer and Director of the IssuerAug 2019
Patrick GallagherDirectorAug 2019
Samuel NavarroDirectorAug 2019
Jeffrey ODonnellDirectorMar 2019
Roy TanakaDirectorMar 2019
Seth FischerDirectorMar 2019
David FoleyDirectorNov 2015
Gregory CashPresident and Chief Executive OfficerNov 2015
Asher HolzerDirectorApr 2015

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.